Roche and KSQ Therapeutics Reach Global License Agreement for KSQ-4279, an Advanced USP1 Inhibitor for Cancer Therapy
Friday, July 14, 2023
The molecule is currently in Phase 1 clinical trials for solid tumors and has shown promising potential based on preclinical data. Under the agreement, Roche will take over the development of KSQ-4279, allowing KSQ to focus on advancing its immunotherapy programs and discovering new targets using its CRISPRomics® platform.
The partnership between KSQ and Roche reflects the growing interest in DDR as a research area in oncology. By targeting USP1, KSQ-4279 offers a novel treatment option for patients with various cancers and significant unmet medical needs. Roche's strategic focus on personalized healthcare aligns well with the goal of tailoring treatments to individual patients.
As part of the agreement, KSQ will receive an upfront payment and may be eligible for additional milestone and royalty payments. Roche has been granted a global license and will assume full responsibility for the further development of KSQ-4279 starting in 2024.
KSQ-4279 is a first-in-class small molecule inhibitor of USP1, a protein involved in DNA damage response. It was identified through KSQ's CRISPRomics® platform as an attractive target for cancer therapy due to its distinct role in DNA damage repair compared to other approaches like PARP inhibitors. Currently, a Phase 1 clinical trial (KSQ-4279-1101) is underway to evaluate the safety and efficacy of KSQ-4279 as a monotherapy and in combination with other treatments in patients with advanced solid tumors.
